Literature DB >> 22517906

Multiple myeloma-related deregulation of bone marrow-derived CD34(+) hematopoietic stem and progenitor cells.

Ingmar Bruns1, Ron-Patrick Cadeddu, Ines Brueckmann, Julia Fröbel, Stefanie Geyh, Sebastian Büst, Johannes C Fischer, Frederik Roels, Christian Matthias Wilk, Frank A Schildberg, Ali-Nuri Hünerlitürkoglu, Christoph Zilkens, Marcus Jäger, Ulrich Steidl, Fabian Zohren, Roland Fenk, Guido Kobbe, Benedict Brors, Akos Czibere, Thomas Schroeder, Andreas Trumpp, Rainer Haas.   

Abstract

Multiple myeloma (MM) is a clonal plasma cell disorder frequently accompanied by hematopoietic impairment. We show that hematopoietic stem and progenitor cells (HSPCs), in particular megakaryocyte-erythrocyte progenitors, are diminished in the BM of MM patients. Genomic profiling of HSPC subsets revealed deregulations of signaling cascades, most notably TGFβ signaling, and pathways involved in cytoskeletal organization, migration, adhesion, and cell-cycle regulation in the patients. Functionally, proliferation, colony formation, and long-term self-renewal were impaired as a consequence of activated TGFβ signaling. In accordance, TGFβ levels in the BM extracellular fluid were elevated and mesenchymal stromal cells (MSCs) had a reduced capacity to support long-term hematopoiesis of HSPCs that completely recovered on blockade of TGFβ signaling. Furthermore, we found defective actin assembly and down-regulation of the adhesion receptor CD44 in MM HSPCs functionally reflected by impaired migration and adhesion. Still, transplantation into myeloma-free NOG mice revealed even enhanced engraftment and normal differentiation capacities of MM HSPCs, which underlines that functional impairment of HSPCs depends on MM-related microenvironmental cues and is reversible. Taken together, these data implicate that hematopoietic suppression in MM emerges from the HSPCs as a result of MM-related microenvironmental alterations.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22517906      PMCID: PMC3460684          DOI: 10.1182/blood-2011-04-347484

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  49 in total

1.  Role of abnormal integrin-cytoskeletal interactions in impaired beta1 integrin function in chronic myelogenous leukemia hematopoietic progenitors.

Authors:  R Bhatia; H A Munthe; C M Verfaillie
Journal:  Exp Hematol       Date:  1999-09       Impact factor: 3.084

2.  A global test for groups of genes: testing association with a clinical outcome.

Authors:  Jelle J Goeman; Sara A van de Geer; Floor de Kort; Hans C van Houwelingen
Journal:  Bioinformatics       Date:  2004-01-01       Impact factor: 6.937

Review 3.  Mechanisms of TGF-beta signaling from cell membrane to the nucleus.

Authors:  Yigong Shi; Joan Massagué
Journal:  Cell       Date:  2003-06-13       Impact factor: 41.582

4.  Characterization of human bone marrow fibroblast colony-forming cells (CFU-F) and their progeny.

Authors:  H Castro-Malaspina; R E Gay; G Resnick; N Kapoor; P Meyers; D Chiarieri; S McKenzie; H E Broxmeyer; M A Moore
Journal:  Blood       Date:  1980-08       Impact factor: 22.113

5.  Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment.

Authors:  Toshiaki Hayashi; Teru Hideshima; Aaron N Nguyen; Olivier Munoz; Klaus Podar; Makoto Hamasaki; Kenji Ishitsuka; Hiroshi Yasui; Paul Richardson; Sarvajit Chakravarty; Alison Murphy; Dharminder Chauhan; Linda S Higgins; Kenneth C Anderson
Journal:  Clin Cancer Res       Date:  2004-11-15       Impact factor: 12.531

6.  SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.

Authors:  Martin Uhl; Steffen Aulwurm; Jörg Wischhusen; Markus Weiler; Jing Ying Ma; Ramona Almirez; Ruban Mangadu; Yu-Wang Liu; Michael Platten; Ulrich Herrlinger; Alison Murphy; Darren H Wong; Wolfgang Wick; Linda S Higgins; Michael Weller
Journal:  Cancer Res       Date:  2004-11-01       Impact factor: 12.701

Review 7.  VLA-4-mediated interactions between normal human hematopoietic progenitors and stromal cells.

Authors:  R A Oostendorp; P Dörmer
Journal:  Leuk Lymphoma       Date:  1997-02

8.  CD44 and hyaluronic acid cooperate with SDF-1 in the trafficking of human CD34+ stem/progenitor cells to bone marrow.

Authors:  Abraham Avigdor; Polina Goichberg; Shoham Shivtiel; Ayelet Dar; Amnon Peled; Sarit Samira; Orit Kollet; Rami Hershkoviz; Ronen Alon; Izhar Hardan; Herzl Ben-Hur; David Naor; Arnon Nagler; Tsvee Lapidot
Journal:  Blood       Date:  2004-01-15       Impact factor: 22.113

9.  High-dose melphalan with autologous bone marrow transplantation for multiple myeloma.

Authors:  B Barlogie; R Hall; A Zander; K Dicke; R Alexanian
Journal:  Blood       Date:  1986-05       Impact factor: 22.113

10.  Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells.

Authors:  M Urashima; A Ogata; D Chauhan; M Hatziyanni; M B Vidriales; D A Dedera; R L Schlossman; K C Anderson
Journal:  Blood       Date:  1996-03-01       Impact factor: 22.113

View more
  32 in total

Review 1.  Cancer stem cells: progress and challenges in lung cancer.

Authors:  Amanda K Templeton; Shinya Miyamoto; Anish Babu; Anupama Munshi; Rajagopal Ramesh
Journal:  Stem Cell Investig       Date:  2014-04-15

2.  Mesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytes.

Authors:  Syed J Mehdi; Sarah K Johnson; Joshua Epstein; Maurizio Zangari; Pingping Qu; Antje Hoering; Frits van Rhee; Carolina Schinke; Sharmilan Thanendrarajan; Bart Barlogie; Faith E Davies; Gareth J Morgan; Shmuel Yaccoby
Journal:  Br J Haematol       Date:  2018-11-08       Impact factor: 6.998

3.  Functional abnormalities and changes in gene expression in fibroblasts and macrophages from the bone marrow of patients with acute myeloid leukemia.

Authors:  Yu Li; Jan Dürig; Maria Göbel; Maher Hanoun; Ludger Klein-Hitpaß; Ulrich Dührsen
Journal:  Int J Hematol       Date:  2015-06-28       Impact factor: 2.490

4.  Hematopoiesis in patients with mature B-cell malignancies is deregulated even in patients with undetectable bone marrow involvement.

Authors:  Bokang Calvin Lenyeletse Maswabi; Jan Molinsky; Filipp Savvulidi; Tomas Zikmund; Dana Prukova; Diana Tuskova; Magdalena Klanova; Petra Vockova; Lucie Lateckova; Ludek Sefc; Jan Zivny; Marek Trneny; Pavel Klener
Journal:  Haematologica       Date:  2017-01-05       Impact factor: 9.941

Review 5.  Macrophages in multiple myeloma: emerging concepts and therapeutic implications.

Authors:  Fotis Asimakopoulos; Jaehyup Kim; Ryan A Denu; Chelsea Hope; Jeffrey L Jensen; Samuel J Ollar; Ellen Hebron; Claire Flanagan; Natalie Callander; Peiman Hematti
Journal:  Leuk Lymphoma       Date:  2013-04-11

6.  How old is too old? In vivo engraftment of human peripheral blood stem cells cryopreserved for up to 18 years - implications for clinical transplantation and stability programs.

Authors:  John Underwood; Mahvish Rahim; Carijo West; Rebecca Britton; Elaine Skipworth; Vicki Graves; Steven Sexton; Hillary Harris; Dave Schwering; Anthony Sinn; Karen E Pollok; Kent A Robertson; W Scott Goebel; Kerry M Hege
Journal:  World J Stem Cells       Date:  2020-05-26       Impact factor: 5.326

Review 7.  The functional interplay between systemic cancer and the hematopoietic stem cell niche.

Authors:  Amber J Giles; Christopher D Chien; Caitlin M Reid; Terry J Fry; Deric M Park; Rosandra N Kaplan; Mark R Gilbert
Journal:  Pharmacol Ther       Date:  2016-09-02       Impact factor: 12.310

Review 8.  Stem cell competition: finding balance in the niche.

Authors:  Rachel R Stine; Erika L Matunis
Journal:  Trends Cell Biol       Date:  2013-04-16       Impact factor: 20.808

Review 9.  Concise review: growth differentiation factor 15 in pathology: a clinical role?

Authors:  Jill Corre; Benjamin Hébraud; Philippe Bourin
Journal:  Stem Cells Transl Med       Date:  2013-11-04       Impact factor: 6.940

10.  Inhibition of Transforming Growth Factor-β Activation Diminishes Tumor Progression and Osteolytic Bone Disease in Mouse Models of Multiple Myeloma.

Authors:  Ailing Lu; Manuel A Pallero; Weiqi Lei; Huixian Hong; Yang Yang; Mark J Suto; Joanne E Murphy-Ullrich
Journal:  Am J Pathol       Date:  2016-01-20       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.